Shane Schaffer

Shane Schaffer is the co-founder, chairman, and chief executive officer at Cingulate Therapeutics, based in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is focused on developing and managing branded next-generation pharmaceutical products, with a particular emphasis on Attention Deficit/Hyperactivity Disorders (ADHD), and extending into other therapeutic areas such as anxiety disorders and insomnia.

​

With over 25 years in the pharmaceutical industry, Shane specializes in drug development and commercialization. His leadership and entrepreneurial skills are evident across various business operations, including product launches, brand planning, joint venture brand management, life cycle management, and market development, establishing him as a notable figure in the biopharmaceutical and marketing circles.

​

Education

​

He earned his doctoral degree in Pharmacy from the University of Kansas in 1999 and subsequently completed a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. During his fellowship, he worked at Pfizer Worldwide Marketing and Morris Plains.

​

He was a marketing manager at Pfizer Worldwide Marketing in New York. He collaboratively developed pre-launch strategies and initiated the Global Communications Intranet to foster effective communication between medical and marketing stakeholders. He also played a role in creating and implementing Pfizer's Medical and Academic Partnership in Pain Management.

​

In Morris Plains, New Jersey, he held the roles of Project Manager and External Research Manager within the Parke-Davis Medical and Scientific Affairs division. He led advanced sales training and managed Phase IV Medical Research across all marketed brands.

​

Professional Career

​

Throughout his career, Shane held various managerial positions at industry giants like Pfizer, Novartis, and Sanofi—including their predecessor companies. At Novartis, he was a Product Manager who successfully launched Ritalin® LA and Focalin™, achieving significant market penetration and product awareness shortly after launch. His work with the ADHD franchise led to numerous accolades, including several Novartis Business Excellence Awards.

​

His tenure at Sanofi-Aventis was marked by leadership roles in the development and strategy implementation for Avapro and Avalide in collaboration with Bristol-Myers Squibb. He also played a crucial role in promoting Hyalgan, Eligard, and Arixtra, receiving multiple Sanofi Star Awards.

​

After leaving Sanofi-Aventis, he joined M|C Communications LLC in Boston as a consultant, managing business operations for numerous pharmaceutical company targets. In July 2009, he founded Sabre Scientific Solutions, LLC, providing significant consulting services across the commercial, clinical, LCM, product launch, and leadership sectors.

​

Cingulate Therapeutics LLC

​

Driven by his passion for ADHD and its treatment, Shane founded Cingulate Therapeutics LLC in January 2013. His vast experience has been pivotal in steering the company towards innovative drug delivery technologies for ADHD and anxiety disorders.

​

Cingulate has partnered with Indegene to market its oral ADHD drug, CTx-1301, which has entered Phase 3 trials. This partnership aims to revolutionize the way ADHD drugs are delivered, potentially reducing dependency on prescribed medications.

​

Philanthropic Contributions

​

Beyond his professional life, Shane Schaffer is committed to philanthropic efforts, mainly through his work with Folds of Honor Charity, which provides scholarships and educational opportunities to children impacted by the loss or disability of a military parent. His dedication extends beyond his business achievements, reflecting his deep commitment to societal contributions and educational support.